Aug. 13 at 12:15 PM
$DMAC
🚨 🚨 🚨
EPS Performance: The reported EPS of (
$0.18) outperformed analyst estimates by approximately 7%
Revenue: As is typical for a clinical-stage biopharmaceutical company, revenue remained at
$0.0, aligning with expectations.
Cash Position: DiaMedica reported
$30.0 million in cash and equivalents at the end of the quarter. A private placement in July 2025 increased their pro forma cash balance to approximately
$60 million as of June 30, 2025, extending their operational runway into the second half of 2027.
Expenses and Net Loss: Research and development expenses rose to
$5.8 million from
$3.9 million in the prior year, mainly due to ongoing clinical trials like the ReMEDy2 study for acute ischemic stroke.
The company also announced positive interim results from the DM199 preeclampsia Phase 2 trial in July 2025, which met all pre-specified safety and efficacy endpoints, showing significant reductions in blood pressure and improved uterine blood flow.
